Filter by: Subject

Filter by: Subject

Results Per Page:

Positron emission tomography/computed tomography (PET/CT) (20)
SDG-03: Good health and well-being (6)
Prostate cancer (4)
18F-fluciclovin PET (2)
18F-fluciclovine PET/CT imaging (2)
68Ga-PSMA PET (2)
Biochemical recurrence (BCR) (2)
Cervical cancer (2)
Fibroblast activation protein inhibitor (FAPI) (2)
Fluorodeoxyglucose (FDG) (2)
Fluorodeoxyglucose positron emission tomography (FDG PET) (2)
Positron emission tomography (PET) (2)
Salvage radiotherapy (SRT) (2)
18 F-fluciclovine PET/CT (1)
18 F-rhPSMA PET/CT (1)
18F-FDG PET/CT (1)
18F-fluorodeoxyglucose (18F-FDG) (1)
18F-fuorodeoxyglucose (FDG) (1)
2‑[18F]‑fluoro‑2‑deoxy‑D‑glucose (1)
68Ga-citrate PET/CT (1)
68Gallium prostate specific membrane antigen (68Ga-PSMA) (1)
68Ga‐PSMA‐617 (1)
[18F]FDG PET/CT (1)
[68Ga]Ga-FAPI PET/CT (1)
Aberrant hepatic vasculature (1)
Accurate image interpretation (1)
Adnexa mass (1)
Adult (1)
Adverse pathology (1)
Alpha(nu)beta(3)-integrin (1)
Angiogenesis (1)
Anthracycline-based chemotherapy (1)
Anthracyclines (1)
Arterial inflammation (1)
Artifact (1)
Biodistribution (1)
Breast uptake (1)
Burkitt lymphoma (BL) (1)
Cancer-associated fibroblast (1)
Case report (1)
Cavernous sinus syndrome (1)
Chest X-ray (1)
Chronic kidney disease-mineral and bone disorder (1)
Computed tomography (CT) (1)
Diagnosis (1)
Diagnostic imaging (1)
EMPIRE-1 trial (1)
Endometrium (1)
F-18 Fluoro Deoxyglucose positron emission tomography and computed tomography (F-18 FDG PET/CT) (1)
Failure-free survival (FFS) (1)
FAPI tumor volume (FAPI-TV) (1)
Fluorine-18 2-fluoro-2-deoxyglucose (18F-FDG) (1)
Fluorine-18-fluorodeoxyglucose (18F-FDG) (1)
Gallium-68 (Ga-68) (1)
Gynecological malignancies (1)
Hodgkin lymphoma (1)
Hypoxia (1)
Hypoxia-inducible factor-1alpha (HIF-1) (1)
Imaging technology (1)
Immunohistochemistry (1)
In vitro (1)
Invasive fungal disease (IFD) (1)
Invasive fungal infection (IFI) (1)
Liver segment IV (1)
Lobular breast cancer (1)
Lung cancer (1)
Luteal cyst (1)
Magnetic resonance imaging (MRI) (1)
Male (1)
Menstrual cycle (1)
Metabolic superscan (1)
Microemulsion (1)
Nota-RGD (1)
Patient management (1)
Patient treatment (1)
Patients (1)
Peptide radiolabeling (1)
PET-based response assessment of radiotherapy (1)
PET/CT-imaging (1)
Pitfall (1)
Prostate specific membrane antigen (PSMA) (1)
Prostate-specific antigen (1)
Prostate-specific membrane antigen (PSMA) (1)
Prostate-specific membrane antigen expression (1)
PSMA PET/CT (1)
Radiation hepatitis (1)
Renal osteodystrophy (1)
Sentinel lymph node (SLN) (1)
Skeletal metastasis progression (1)
Solitary pulmonary nodules (SPN) (1)
South Africa (SA) (1)
Standardized uptake values (SUV) (1)
Tripeptide arginyl-glycyl-asparatic acid (RGD) (1)
Tuberculosis (TB) (1)
Tumor-to-background ratios (TBR) (1)
Ultrasound (1)
Uterine leiomyoma (1)
Various cancer diseases (1)
Vascular beds (1)
Volumes of interest (VOIs) (1)